Therapeutics of Wegener's granulomatosis

Nature Clinical Practice Rheumatology

Volumn 2, Issue 4, 2006, Pages 192-200

  Wung, Peter K ^a   Stone, John H ^b  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antineutrophil cytoplasmic antibody; Cyclophosphamide; Vasculitis; Wegener's granulomatosis

Indexed keywords

15 DEOXYSPERGUALIN; ATOVAQUONE; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAPSONE; ESTROGEN; ETANERCEPT; FOLIC ACID; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; PLACEBO; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; VITAMIN D;

ANCA ASSOCIATED VASCULITIS; BLADDER CANCER; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONDUCTION DEAFNESS; CREATININE CLEARANCE; CYTOPENIA; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FEMALE INFERTILITY; FOLIC ACID DEFICIENCY; FOLLOW UP; FRAGILITY FRACTURE; GLOMERULONEPHRITIS; HEMORRHAGIC CYSTITIS; HEPATITIS; HUMAN; KIDNEY DYSFUNCTION; LEUKEMIA; LEUKOPENIA; LIVER DYSFUNCTION; LONG TERM CARE; LUNG HEMORRHAGE; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MICROSCOPIC POLYANGIITIS; MONONEUROPATHY MULTIPLEX; MORBIDITY; NAUSEA AND VOMITING; NOSE ULCER; OPPORTUNISTIC INFECTION; OSTEOPENIA; OSTEOPOROSIS; OVARY INSUFFICIENCY; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; RHINORRHEA; SUBGLOTTIC STENOSIS; TRANSITIONAL CELL CARCINOMA; WEGENER GRANULOMATOSIS;

GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR NECROSIS FACTORS; WEGENER GRANULOMATOSIS;

EID: 33645708597     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0139     Document Type: Review

References (54)

1. Cotch MF et al. (1996) The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 39: 87-92
2. Hoffman GS et al. (1992) Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med 116: 488-498
3. Reinhold-Keller E et al. (2000) An interdisciplinary approach to the care of patients with Wegener's granulomatosis: Long-term outcome in 155 patients. Arthritis Rheum 43:1021-1032
4. Stone JH (2003) Limited versus severe Wegener's granulomatosis: Baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 48: 2299-2309
5. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352: 351-361
6. Klinger H (1931) Grenzformen der periarteritis nodosa [German]. Frankfurt Z Pathol 42: 455-480
7. Wegener F (1936) Über generalisierte, septische gefasserkrankungen [German]. Verh Dtsch Ges Pathol 29: 202-210
8. Wegener F (1939) Über eine eigenartige rhinogene granulomatose mit besonderer beteiligung des Arteriensystems und der Nieren [German]. Beitr Pathol Anat Allg Pathol 36: 36-68
9. Walton EW (1958) Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 34: 265-270
10. Hollander D and Manning RT (1967) The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med 67: 393-398
11. Fauci AS et al. (1971) Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med 285: 1493-1496
12. Hoffman GS et al. (1992) The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 35: 1322-1329
13. WGET Research Group (2002) Design of the Wegener's granulomatosis etanercept trial (WGET). Control Clin Trials 23: 450-468
14. Seo P et al. (2005) Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's granulomatosis etanercept trial (WGET). Arthritis Rheum 52: 2168-2178
15. Haubitz M et al. (1998) Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study. Arthritis Rheum 41: 1835-1844
16. Guillevin L et al. (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 40: 2187-2198
17. De Groot K et al. (2005) Randomised controlled trial of daily oral versus pulse cyclophosphamide for induction of remission in ANCA-associated systemic vasculitis. Kidney Blood Press Res 28: 195
18. De Groot K et al. (1998) Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 25: 492-495
19. Langford CA et al. (2000) Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 43: 1836-1840
20. Sneller MC et al. (1995) An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 38: 608-613
21. De Groot K et al. (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 2461-2469
22. Goek ON and Stone JH (2005) Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies. Curr Opin Rheumatol 17: 257-264
23. Langford CA et al. (2003) Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: Extended follow-up and rate of relapse. Am J Med 114: 463-469
24. Reinhold-Keller E et al. (2002) High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 47: 326-332
25. Jayne D et al. (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349: 36-44
26. Russian DA and Levine SJ (2001) Pneumocystis carinii pneumonia in patients without HIV infection. Am J Med Sci 321: 56-65
27. Yale SH and Limper AH (1996) Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: Associated illness and prior corticosteroid therapy. Mayo Clin Proc 71: 5-13
28. Gluck T et al. (2000) Pneumocystis carinii pneumonia as a complication of immunosuppressive therapy. Infection 28: 227-230
29. Krebs S and Gibbons RB (1996) Low-dose methotrexate as a risk factor for Pneumocystis carinii pneumonia. Mil Med 161: 58-60
30. El-Sadr WM et al. (1998) Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med 339: 1889-1895
31. Shepherd JD et al. (1991) Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 9: 2016-2020
32. Hows JM et al. (1984) Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in bone marrow transplantation: A prospective randomised study. Br J Cancer 50: 753-756
33. Hellmich B et al. (2004) Urinary bladder cancer in Wegener's granulomatosis: Is it more than cyclophosphamide? Ann Rheum Dis 63: 1183-1185
34. Compston J (2004) US and UK guidelines for glucocorticoid-induced osteoporosis: Similarities and differences. Curr Rheumatol Rep 6: 66-69
35. Vestergaard P et al. (2005) Fracture risk associated with systemic and topical corticosteroids. J Intern Med 257: 374-384
36. Bischoff-Ferrari HA et al. (2005) Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA 293: 2257-2264
37. Banks E et al. (2004) Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 291: 2212-2220
38. Stegeman CA et al. (1996) Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 335: 16-20
39. Klemmer PJ et al. (2003) Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 42: 1149-1153
40. Jayne DR and Lockwood CM (1996) Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 35: 1150-1153
41. Jayne DR et al. (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93: 433-439
42. Schmitt WH et al. (2004) Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): An open study in 15 patients. Kidney Int 65: 1440-1448
43. van der Woude FJ et al. (2001) Immunosuppression in ANCA-associated vasculitis. Transplant Proc 33: 2225-2226
44. Booth AD et al. (2004) Infliximab improves endothelial dysfunction in systemic vasculitis: A model of vascular inflammation. Circulation 109: 1718-1723
45. Bartolucci P et al. (2002) Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: An open pilot study on 10 patients. Rheumatology (Oxf) 41: 1126-1132
46. Lamprecht P et al. (2002) Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxf) 41: 1303-1307
47. Keogh KA et al. (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 262-268
48. Metzler C et al. (2004) Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxf) 43: 315-320
49. Langford CA et al. (2004) Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 51: 278-283
50. Nowack R et al. (1999) Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: A pilot study in 11 patients with renal involvement. J Am Soc Nephrol 10: 1965-1971
51. Holcombe H et al. (2002) The immunosuppressive agent 15-deoxyspergualin functions by inhibiting cell cycle progression and cytokine production following naive T cell activation. J Immunol 169: 4982-4989
52. Wang B et al. (1996) The immunosuppressant 15-deoxyspergualin reveals commonality between preT and preB cell differentiation. J Exp Med 183: 2427-2436
53. Birck R et al. (2003) 15-deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: A six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 14: 440-447
54. Schmitt WH et al. (2005) Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: An open study in seven patients. Nephrol Dial Transplant 20: 1083-1092